Study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma
Heather Buschman, PhD
Advertisement
Articles by Heather Buschman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
5